Table 2.
Patient characteristics
| Characteristics | |
|---|---|
| Age, years | |
| Mean (median) | 49.5 (50) |
| 95% confidence interval | 25–65 |
| Sex, n (%) | |
| Female | 50 (100) |
| Male | 0 (0) |
| Performance status (ECOG), n (%) | |
| 0 | 3 (60) |
| 1 | 12 (24) |
| 2 | 8 (16) |
| Cancer type, n (%) | |
| Ovarian | 35 (70) |
| Breast | 10 (20) |
| Endometrial | 5 (10) |
| Paclitaxel, n (%) | |
| Single agent (initial dose) | |
| Weekly (80 mg/m2) | 14 (28) |
| Thrice weekly (175 mg/m2) | 29 (58) |
| Combination | |
| With carboplatin | 7 (14) |
| With other agents | 0 (0) |
| Paclitaxel setting, n (%) | |
| Neoadjuvant/adjuvant | 40 (80) |
| Metastatic/recurrent | 10 (20) |
| Prior treatment, n (%) | |
| Chemotherapy | 5 (10) |
| Radiotherapy to chest wall | 5 (10) |
| Associated comorbidities, n (%) | |
| Hypertension | 20 (40) |
| Hypercholesterolemia | 18 (36) |
| Diabetes mellitus | 5 (10) |
| Ischemic heart disease | 3 (6) |
| Total, n (%) | 50 (100) |